Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.5, and our video podcast, CANCER BUZZ TV.
Log in

Industry News Archive

Updated Data for Durvalumab

Durvalumab (Imfinzi®, AstraZeneca) offers the best chance for long-term survival in a curative intent setting. This update comes after the post-hoc analysis of 5-year overall and progression-free survival data had been released for the PACIFIC trial, a large, Phase III, randomized, double-blind, placebo-controlled, multicenter study of 713 patients with unresectable Stage III NSCLC. The primary overall survival analysis was reported at 2 years (25.2 months median follow-up). For more information, click here

Posted 6/10/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us